|Podcasts|March 16, 2023

Tearing Down Silos to Usher Innovative Medicines to Patients Faster

Fran Pollaro talks with Cathi Ahearn, senior vice president, worldwide commercial portfolio strategy, Bristol Myers Squibb about impediments and solutions to break down silos in order to get medications in the hands of patients faster.

Cathi Ahearn is a seasoned biotechnology leaders with formative stints at Genentech, Roche, and now at Bristol Myers Squibb, as SVP of worldwide commercial portfolio strategy. Cathi is focused on one goal: shortening the path between creating medical innovation and getting that innovation to patients. Cathi chats with senior editor at Pharmaceutical Executive about her experiences in the past 20+ years and most importantly, the power of cross-functional collaboration, bringing different teams together and tearing down silos that limit the impact new innovations can have for patients.

About the speaker

Cathi joined Bristol Myers Squibb in December 2021 to lead Worldwide Commercial Portfolio Strategy, including responsibility for commercial development of pipeline assets, global marketing of in-line brands, and optimized management of the established brands franchise. She is a seasoned biotechnology leader who spent 22 years in roles of increasing responsibility and scope at Roche/Genentech, primarily in oncology. Her strategic, results-driven mindset led to demonstrated successes building and developing successful teams. Most recently, she led the GI & GU and Cancer Immunotherapy franchises within Roche’s worldwide commercial organization. Cathi led the cross-functional lifecycle & franchise teams for Tecentriq, Roche’s anti-PDL1 program, from the time of its entry into clinic through its global licensing and commercialization. Cathi held a broad range of US sales, marketing, and strategic roles on the Avastin program, and in the cardiovascular and asthma/allergy disease areas.

Cathi holds a Bachelor of Arts in Psychology from UCLA and a Master of Business Administration from the Fuqua School of Business at Duke University.

About the Pharm Exec Podcast

The editors of Pharmaceutical Executive bring you the latest commercial insights to master the science of success. Podcast episodes examine current trends, key conferences, and critical topics in the bio/pharmaceutical industry.

Listen to this podcast on SoundCloudSpotifyGoogle Podcasts, or Apple Podcasts.


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Pharmaceutical Executive daily
FDA approves Kerendia as the first new treatment for kidney disease in type 1 diabetes in decades, Novo, Roche, and Aethlon Medical strike major deals and mergers with Orbis Medicines, Dualitas Therapeutics, and North Immunology, and Thani Jambulingam of Saint Joseph's University examines the fight to control the GLP-1 patient journey.
Pharmaceutical executive daily
GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership with Cheplapharm, Stewart Gandolf discusses why pharma marketing now has to write for both people and AI, and Dr. Elena Christofides explains why cortisol dysregulation may be the hidden reason some diabetes patients fail to respond to incretin therapies.